US2007027331A1PendingUtilityA1
Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
Est. expiryFeb 24, 2024(expired)· nominal 20-yr term from priority
Inventors:Ragina Naidu
C07D 305/14
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A process is provided for the semi-synthesis of taxane intermediates and aziridine analogues of cephalomannne and baccatin III intermediates, and the conversion of such intermediates and analogues to paclitaxel and docetaxel.
Claims
exact text as granted — not AI-modified1 . A process for preparing a taxane comprising the steps of:
converting cephalomannine to a taxane intermediate having the structure: wherein R is at each occurrence independently selected from hydrogen and a hydroxy-protecting group; and converting the taxane intermediate to paclitaxel or docetaxel.
2 . The process of claim 1 wherein the taxane intermediate is converted to paclitaxel.
3 . The process of claim 1 wherein the taxane intermediate is converted to docetaxel.
4 . The process of claim 1 wherein the step of converting cephalomannine to the taxane intermediate further comprises the steps of:
converting cephalomannine to a cephalomannine aziridine analogue having the structure: wherein R is at each occurrence independently selected from hydrogen and a hydroxy-protecting group; and converting the cephalomannine aziridine analogue to the taxane intermediate.
5 . The process of claim 1 wherein the step of converting cephalomannine to the taxane intermediate comprises reacting cephalomannine with formic acid.
6 . The process of claim 1 wherein the step of converting cephalomannine to the taxane intermediate further comprises the reaction sequence:
wherein R is at each occurrence independently selected from hydrogen and a hydroxy-protecting group.
7 . The process of claim 1 wherein the step of converting cephalomannine to the taxane intermediate further comprises the steps of:
converting cephalomannine to a cephalomannine epoxide analogue having the structure: wherein R is at each occurrence independently selected from hydrogen and a hydroxy-protecting group; converting the cephalomannine epoxide analogue to a cephalomannine azido alcohol analogue having the structure: wherein R is at each occurrence independently selected from hydrogen and a hydroxy-protecting group; and converting the cephalomannine azido alcohol analogue to the taxane intermediate.
8 . A process for preparing a taxane comprising the steps of:
converting cinnamoyl halide to a cinnamoyl halide aziridine intermediate having the structure: wherein X is halogen; reacting the cinnamoyl halide aziridine intermediate with protected baccatin III to provide a protected baccatin III aziridine intermediate having the structure: wherein R is selected from hydrogen and a hydroxy-protecting group; converting the protected baccatin III aziridine intermediate to a taxane intermediate having the structure: wherein R is selected from hydrogen and a hydroxy-protecting group; and converting the taxane intermediate to paclitaxel or docetaxel.
9 . The process of claim 8 , wherein X is chloro.
10 . A process for preparing a taxane comprising the steps of:
converting cinnamoyl halide to a cinnamoyl halide aziridine intermediate having the structure: wherein X is halogen; converting the cinnamoyl halide aziridine intermediate to an open chain cinnamoyl halide intermediate having the structure: wherein X is halogen; reacting the open chain cinnamoyl halide intermediate with protected baccatin III to provide a protected baccatin III intermediate having the structure: wherein R is selected from hydrogen and a hydroxy-protecting group; converting the protected baccatin III intermediate to a taxane intermediate having the structure: wherein R is selected from hydrogen and a hydroxy-protecting group; and converting the taxane intermediate to paclitaxel or docetaxel.
11 . The process of claim 10 , wherein X is chloro.
12 . The process of claim 10 , wherein the step of reacting the open chain cinnamoyl halide intermediate with protected baccatin III further comprises the steps of:
converting the open chain cinnamoyl halide intermediate to a β-lactam intermediate having the structure: reacting the β-lactam intermediate with protected baccatin III to provide the protected baccatin III intermediate.
13 . A process for preparing docetaxel from cephalomannine comprising the reaction sequence:
wherein R is at each occurrence independently selected from hydrogen and a hydroxy-protecting group.Join the waitlist — get patent alerts
Track US2007027331A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.